Cancer drug spending climbs, with top winners earning lion's share

Oncology is a lucrative field for pharma, but the payoff is heavily concentrated around just a few dozen medicines, finds a new report from the Iqvia Institute for Human Data Science. The top 35 cancer drugs by sales accounted for 80% of the roughly $110 billion spent globally on oncology therapeutics last year, according to Iqvia.